Archive | Publications

Immunocore’s Lead Asset Tebentafusp Gains Fast Track Designation for Metastatic Uveal Melanoma

Source: Business Wire, May 2019 OXFORD, England & CONSHOHOCKEN, Pa.–(BUSINESS WIRE)–Immunocore Limited, a leading T Cell Receptor (TCR) biotechnology company, today announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its development program, the investigation of tebentafusp (IMCgp100) for the treatment of patients who are HLA-A*0201-positive with previously untreated, metastatic uveal […]

Read the full story

Posted in Melanoma News, Regulatory, Publications

Is your melanoma hot enough for immunotherapy?

Source: Science Daily, May 2019 Melanomas tend to be “hot” or “cold” — if they’re hot, immunotherapy lights melanoma tumors like beacons for elimination by the immune system; but 40-50 percent of melanomas are cold, making them invisible to the immune system, and patients with cold tumors tend to show little benefit from immunotherapies. The […]

Read the full story

Posted in Melanoma News, Regulatory, Publications

MRV Newletter Issue 10, May 2019

 

Read the full story

Posted in MRV Newsletters, Publications

Patterns of recurrence and retreatment outcomes among clinical stage I and II head and neck melanoma patients

Source: MDLinx, April 2019 Authors evaluated the survival outcomes in candidates who underwent retreatment of recurrent cutaneous melanoma of the head and neck between January 1, 2000, and December 31, 2015. Development of recurrence was observed in 33 cases. At last follow-up, they found 66% of candidates who developed local recurrence first and 50% of […]

Read the full story

Posted in Melanoma News, Publications, Scientific Publications